vs
Side-by-side financial comparison of Dingdong (Cayman) Ltd (DDL) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Dingdong (Cayman) Ltd is the larger business by last-quarter revenue ($115.3M vs $70.6M, roughly 1.6× Viridian Therapeutics, Inc.\DE). Dingdong (Cayman) Ltd runs the higher net margin — 5.8% vs -49.0%, a 54.8% gap on every dollar of revenue.
Dingdong (Cayman) Ltd operates a leading on-demand grocery e-commerce platform primarily serving the Chinese market. It provides fresh produce, daily necessities, ready-to-eat meals, and household staples to urban consumers, leveraging optimized supply chains and localized logistics networks to offer fast, reliable 30-minute delivery services, prioritizing product freshness and user convenience.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
DDL vs VRDN — Head-to-Head
Income Statement — Q3 FY2022 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.3M | $70.6M |
| Net Profit | $6.7M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 5.3% | -56.7% |
| Net Margin | 5.8% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $-0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $70.6M | ||
| Q3 22 | $115.3M | — | ||
| Q2 22 | $136.7M | — | ||
| Q1 22 | $118.5M | — |
| Q3 25 | — | $-34.6M | ||
| Q3 22 | $6.7M | — | ||
| Q2 22 | $717.6K | — | ||
| Q1 22 | $10.4M | — |
| Q3 25 | — | -56.7% | ||
| Q3 22 | 5.3% | — | ||
| Q2 22 | 0.0% | — | ||
| Q1 22 | 8.2% | — |
| Q3 25 | — | -49.0% | ||
| Q3 22 | 5.8% | — | ||
| Q2 22 | 0.5% | — | ||
| Q1 22 | 8.8% | — |
| Q3 25 | — | — | ||
| Q3 22 | $-0.02 | — | ||
| Q2 22 | $-0.00 | — | ||
| Q1 22 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $113.7M | $490.9M |
| Total DebtLower is stronger | $135.8K | — |
| Stockholders' EquityBook value | $4.5M | $503.0M |
| Total Assets | $178.3M | $577.1M |
| Debt / EquityLower = less leverage | 0.03× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $490.9M | ||
| Q3 22 | $113.7M | — | ||
| Q2 22 | $124.9M | — | ||
| Q1 22 | $105.6M | — |
| Q3 25 | — | — | ||
| Q3 22 | $135.8K | — | ||
| Q2 22 | $322.0K | — | ||
| Q1 22 | $527.9K | — |
| Q3 25 | — | $503.0M | ||
| Q3 22 | $4.5M | — | ||
| Q2 22 | $8.5M | — | ||
| Q1 22 | $5.9M | — |
| Q3 25 | — | $577.1M | ||
| Q3 22 | $178.3M | — | ||
| Q2 22 | $194.3M | — | ||
| Q1 22 | $187.7M | — |
| Q3 25 | — | — | ||
| Q3 22 | 0.03× | — | ||
| Q2 22 | 0.04× | — | ||
| Q1 22 | 0.09× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-84.6M | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | — | $-84.7M | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | — | -120.1% | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
| Q3 25 | — | 0.2% | ||
| Q3 22 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
